11/06/19

Hizlaria / Ponente: Rui E. Castro (Ph.D) – Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa).
Data / Fecha: 2019ko ekainak 11 / 11 de junio de 2019.
Ordua / Hora:  9:30-10:30.
Lekua / LugarBiodonostia OIIko Ekitaldi Aretoan, 0.Solairua. / IIS Biodonostia, Salón de Actos, Planta 0.

Laburpena / Resumen:
Rui Castro graduated in Biology and Genetics and completed his PhD in Pharmacy (Biochemistry) by the Faculty of Pharmacy, University of Lisbon (FFUL) and Department of Medicine, University of Minnesota Medical School, USA. He is now Assistant Professor and Principal Investigator at the Research Institute for Medicines (iMed.ULisboa), FFUL. He is a strong promoter of basic and translational to clinical research in Hepatology, being a member of both the EASL Education Committee and the UEG Education E-Learning Team.
Castro’s research combines his solid background in the modulation of liver cell function by bile acids with his most recent discoveries in the miRNA field, to answer fundamental questions on the pathogenesis and therapeutic targeting of liver diseases, focusing on non-alcoholic fatty liver disease. Well-established in vitro and in vivo models, as well as human patients liver biopsies and serum samples, are being used in multi-layered pharmacological approaches, aiming to ultimately bring miRNA therapies and biomarkers to the liver clinical setting.